Septerna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors?

Septerna, a clinical-stage biotech focused on GPCR-targeted therapies, reported significant insider selling in its latest SEC filing.

CryptoAlerta — análise de criptomoedas e mercado em tempo real